5 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 5 of 5 clinical reviews.
Evidence-based guide to bremelanotide (PT-141) dosing in East Asian populations, covering pharmacogenomic factors, body weight considerations, CYP enzyme polymorphisms, and clinical recommendations.
Evidence-based guide to bremelanotide (PT-141) dosing considerations in South Asian populations, covering pharmacogenomics, cardiovascular screening, and clinical recommendations.
An evidence-based review of bremelanotide (PT-141) pharmacogenomics, efficacy data, and dosing considerations in Hispanic and Latino patients, including RECONNECT trial subgroup analysis and CYP enzyme variation.
A analysis of PT-141 (bremelanotide) efficacy in South Asian patients, covering pharmacogenomic differences, cardiovascular risk overlaps, and practical dosing considerations backed by trial data and guideline references.
A clinical deep-dive into how PT-141 (bremelanotide) behaves differently in South Asian patients, covering pharmacogenomics, cardiovascular risk, dosing adjustments, and ethnicity-specific safety considerations backed by primary medical literature.